1569 results about "Dimer" patented technology

The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.

Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product D-dimer antibody and application thereof. According to the application, a single B cell antibody preparation technology and a flow cytometry sorting method are applied to the development of a blood coagulation in-vitro diagnosis fibrinolysis system detection antibody for the first time, and a mammalian cell expression system (293F) is adopted to successfully express and obtain three strains of D-dimer monoclonal antibodies (antibody numbers are DD-1, DD-2 and DD-3) with biological activity. Compared with the on-sale Roch D-dimer antibody, the three antibodies have the same affinity with the DD antigen, and can identify and detect the D-dimer in plasma with high specificity and high sensitivity; meanwhile, the probe has no cross reaction with fibrinogen, primary fibrinolytic substances (X, Y and D) and soluble fibrin (SF), and can be used for qualitative or quantitative detection of D-dimer.

The invention discloses an arginine decarboxylase diaA enzyme mutant and application thereof in preparation of butanediamine, and belongs to the field of bioengineering. According to the invention, rational charge overturning transformation is simultaneously carried out on a pentamer meridian oligomeric interface and a dimer latitudinal oligomeric interface, so that stable assembly and efficient catalysis of the decamer under the condition of neutral to alkaline pH (7.0-9.0) are realized. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD110K / H736E at pH 8.0 is about 35 times that of a wild type, and the representative double mutant AdiAD110K / H736E keeps a complete decamer state in a pH range of 7.0-9.0. The yield of butanediamine is up to 145.9 g / L under the whole-cell catalysis of the mutant.

The invention relates to the technical field of molecular imaging probes, in particular to a CXCR4 receptor targeting dimer labeling precursor and a radioactive tracer derived from the same. Compared with [68Ga] Ga-SDNUM01, the radioactive tracer agent [68Ga] Ga-SDNUM04 derived from the targeted CXCR4 receptor dimer labeled precursor provided by the invention has the advantages that the retention time of the radioactive tracer agent [68Ga] Ga-SDNUM04 in tumors is longer, and the radioactive tracer agent [68Ga] Ga-SDNUM04 can also show an excellent imaging effect within 45 minutes.

The invention discloses a rational copolymerization strategy for improving the stability of an oligomeric structure of acid-induced high-order oligomeric decarboxylase AdiA in a neutral to alkaline environment and application of the rational copolymerization strategy, and belongs to the field of bioengineering. According to the strategy, rational charge overturning transformation is carried out on a pentamer radial oligomeric interface and a dimer weft-wise oligomeric interface at the same time, and stable assembly and efficient catalysis of a decamer under the condition that the pH value is from 7.0 to 9.0 from neutral to alkaline are achieved. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD471K / E467K / H736E is 45.5 times that of a wild type when the pH value is 8.0, and the representative double mutant AdiAD471K / E467K / H736E keeps a complete decamer state when the pH value is 7.0-9.0. The yield of butanediamine is up to 156.5 g / L by using the mutant to catalyze whole cells.

The invention discloses a method for evaluating the possibility that complementary regions among primers in a candidate primer group trigger generation of dimers, complementary subregions in primer sequences are HBJ regions, the possibility that the HBJ regions trigger the dimers is represented by a function LHSm of a mathematical model (1), the higher the value of the LHSm is, the higher the possibility that the dimers are triggered is, and the lower the value of the LHSm is, the higher the possibility that the dimers are triggered is. According to the evaluation and optimization method disclosed by the invention, the formation of primer dimers can be reduced to the maximum extent.

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

The invention discloses a dimeric electron acceptor, which has one of the following structural formula: # imgabs0 #, in which R1 and R2 are respectively and independently selected from C1-C100 alkyl groups; x comprises H, F, Cl, I, NO2 or CN. According to the dimeric electron acceptor, a 3, 4-ethylenedioxythiophene or 3, 4-dimethoxythiophene unit serves as a connecting unit, an alkoxy side chain is connected to an outer side chain, the open-circuit voltage Voc of a solar cell device with the dimeric electron acceptor as an acceptor material can reach 1.02 V, the energy conversion efficiency PCE is 15.1%, and the dimeric electron acceptor is Vocgt reported at present; and the maximum value of PCE in a dimer acceptor system of 1V. The invention also provides a preparation method of the dimer electron acceptor and an organic photovoltaic device containing the dimer electron acceptor.

The invention discloses a primer set determination method and device, which can be applied to the technical field of biological medicine, and comprises the following steps: calculating the dimer score of each pair of primers and constructing a dimer score matrix, screening out primer pairs with scores lower than a threshold value, and directly excluding primer combinations which are easy to form dimers. The Gibbs free energy matrix is used for further screening, the larger the absolute value of the Gibbs free energy is, the more stable the dimer is, and the primer pairs with overlarge absolute values of the free energy are eliminated through comparison with a threshold value. Finally, the Gibbs free energy is corrected through a loss function, a corrected free energy matrix is obtained, the corrected free energy is combined with the influence of non-standard base pairing, the probability of dimer formation is further accurately evaluated, and a better primer pair is screened out again. Through multiple rounds of strict screening, the formation probability of the primer dimer is reduced to the greatest extent, so that the occurrence of false positive results caused by the primer dimer is effectively reduced, and the occurrence probability of the false positive rate is further reduced.

The invention discloses an anti-D-dimer monoclonal antibody and application thereof, and relates to the technical field of D-dimer detection. The sequence of CDR1-3 of a heavy chain variable region of the anti-D-dimer monoclonal antibody is as shown in SEQ ID NO.1-3 or has at least 95% of homology with the sequence as shown in SEQ ID NO.1-3; amino acid sequences of CDR1 and 3 of the light chain variable region are shown as SEQ ID NO.4 and SEQ ID NO.5 or have at least 95% of homology with the sequences shown as SEQ ID NO.4 and SEQ ID NO.5; and the CDR2 sequence of the light chain variable region is DTS. The monoclonal antibody has very high titer and specificity to the D-dimer, the sensitivity of the monoclonal antibody is equivalent to that of products of imported well-known manufacturers, the plateau phase of a change curve during antigen-antibody reaction can be greatly prolonged, and the false negative probability caused by too high DD content in a specimen during clinical use is greatly reduced.

The invention provides a sesquiterpene dimer in artemisia selengensis, a pharmaceutical composition of the sesquiterpene dimer and a preparation method and application of the sesquiterpene dimer, and belongs to the technical field of medicines. According to the present invention, the eight new sesquiterpene dimers represented by the structural formula of the present invention, artemselenoids A-H (1-8) have significant inhibitory activity on three liver cancer cells (HepG2, Huh7 and SK-Hep-1), can form the pharmaceutical composition with the pharmaceutically acceptable carrier, and can be used for preparing the anti-liver cancer drug.

The disclosed technology provides a vitrimeric poly(diketoenamine) network comprising: a plurality of multifunctional triketone dimers; a plurality of multifunctional amine species containing primary or secondary amine groups, but no tertiary amine groups; and optionally, one or more amine-reactive groups. The disclosed technology also provides a method of making a vitrimeric polymer network, comprising: obtaining multifunctional triketone dimers; obtaining a multifunctional imine compound, with imine groups blocking amine groups; mixing the multifunctional triketone dimers with the multifunctional imine compound, thereby forming a polymer precursor mixture; applying the polymer precursor mixture onto a substrate; and allowing the multifunctional imine compound to undergo hydrolysis with water, unblocking the amine functional groups and generating a multifunctional amine compound. The multifunctional amine compound reacts with the multifunctional triketone dimers to form a vitrimeric polymer network. The vitrimeric polymer network may be depolymerized back to monomers, which may be repolymerized in a closed-loop system.

The present invention provides an amidinate compound represented by the following general formula (1) or a dimer compound thereof, and a method of producing a thin-film including using the compound as a raw material:where R1 and R2 each independently represent an alkyl group having 1 to 5 carbon atoms, R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, M represents a metal atom or a silicon atom, and “n” represents the valence of the atom represented by M, provided that at least one hydrogen atom of R1 to R3 is substituted with a fluorine atom.

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The present invention belongs to the technical field of polyamide 6 synthesis, and relates to a method for inhibiting the formation of infusible cyclic dimers of polyamide 6 and an application thereof. A method for inhibiting the formation of infusible cyclic dimers of polyamide 6 is to add an amino acid in the ring opening stage and the polycondensation stage respectively during the process of synthesizing polyamide 6 from caprolactam by hydrolysis, wherein the amino acid is an amino acid other than aminocaproic acid. An application is to synthesize a polyamide 6 by adopting the method for inhibiting the formation of infusible cyclic dimers of polyamide 6. The present invention reduces the proportion of original infusible cyclic dimers at thermodynamic equilibrium by adding an amino acid at different stages, thereby improving the melt quality, avoiding the influence of infusible cyclic dimers on the melt spinning process, and meeting the processing requirements of direct high-speed spinning.

Provided is a bispecific antibody against EGFR and c-MET. By means of engineering the amino acid sequences of the Fc segments of binding arms, a KIH structure is formed between the EGFR binding arm and C-Met binding arm of the bispecific antibody, thereby assembling a heterodimer. The bispecific antibody is capable of inhibiting the growth and proliferation of EGFR and / or c-Met positive human tumor cells, mediating antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and mediating the internalization and degradation of dual target proteins of EGFR and c-MET, and also has a synergistic effect. The bispecific antibody is simple to prepare and stable in structure, and is expected to better meet clinical treatment requirements on the basis of a better tumor cell selectivity.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention discloses a method for detecting related substances in atosiban acetate and a preparation thereof, and belongs to the technical field of chemical analysis. According to the method, a high performance liquid chromatography method is adopted, a C18 chromatographic column is used as a stationary phase, an ultraviolet detector is used as a detector, a buffer salt solution-organic phase is used as a mobile phase, and a gradient elution procedure is adopted to detect the content of related substances in atosiban acetate and the preparation thereof. The related substances comprise Di-Gly9-atosiban, delta-Ava7-atosiban, Des-Gly9-atosiban, Gly9-ol-atosiban, Asp5-atosiban, Gly9-OH-atosiban, a dimer (Gly-Orn), and Des-Gly-Aminoperperidine8-atosiban, and the related substances are used for preparing the medicine for preventing and treating ovarian cancer. The medicine for preventing and treating ovarian cancer can be used for preventing and treating ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer and the like. The method has the advantages of strong specificity, good repeatability and high accuracy, and can effectively control the quality of atosiban acetate and preparation products thereof.

The invention provides a dimer acceptor material as well as a preparation method and application thereof. The structural general formula of the dimer type acceptor material is (I), and the dimer type acceptor material is constructed by taking a rigid unit with a pi conjugated structure as a bridging unit. The acceptor material has a relatively high glass transition temperature and a relatively low diffusion coefficient. The material is used in a photoelectric functional device, can stabilize the film morphology of an active layer, and finally can effectively improve the stability of the device, for example, as an active layer acceptor material of an organic solar cell, can promote commercial application of the organic solar cell.

The invention discloses a monoclonal antibody which only specifically recognizes neutrophil apolipoprotein homodimer HNL / HNL and does not recognize monomer form HNL. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody realizes accurate, simple and rapid quantification of homodimer form HNL / HNL, promotes wide clinical application of the detection index, accurately distinguishes bacterial infection and virus infection, and reduces unreasonable use of antibiotics.

The invention belongs to the technical field of biological medicine, and particularly relates to a T cell receptor capable of recognizing KRAS G12V antigen oligopeptide, a compound, a pharmaceutical composition and application. The T cell receptor can be used for recognizing a KRAS G12V-HLA-A * 11: 01 compound with high affinity; the T cell receptor is an alpha-beta heterodimer consisting of an alpha chain and a beta chain; the amino acid sequence of the alpha chain is as shown in SEQ ID NO.10, or an amino acid sequence with at least 90% of sequence identity with the alpha chain; the amino acid sequence of the beta chain is as shown in SEQ ID NO.14, or has an amino acid sequence with at least more than 90% of sequence identity with the beta chain. The T cell receptor provided by the invention can be used for preparing medicines for treating tumors or other immune diseases.

The invention relates to a porcine reproductive and respiratory syndrome virus (PRRSV) dimer nucleocapsid (N) protein (PRRSV N-dimer) and application thereof. The PRRSV N-dimer is formed by connecting N protein amino acid sequences in series through (GGGGS) 3linker. According to the invention, a GGGGS 3linker nucleotide sequence is connected in series with a PRRSV NADC30-like strain N protein gene sequence to construct a prokaryotic expression vector, and a recombinant PRRSV N-dimer is expressed in escherichia coli. Through SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and Western-blot detection, the recombinant PRRSV N-dimer obtains soluble expression and can be subjected to a specific reaction with PRRSV positive serum; through detection by a freeze thawing method and an ELISA (Enzyme-Linked Immunosorbent Assay) method, compared with a PRRSV monomer N protein (PRRSV N-monomer), the PRRSV N-dimer protein can be stably preserved, and the immunoreactivity is better. A PRRSV antibody indirect enzyme-linked immunosorbent assay (iELISA) detection method is established on the basis of a PRRSV N-dimer, and can be applied to diagnosis and monitoring of PRRSV infection.

The invention is applicable to the technical field of biological medicines, and provides application of Paquinimod in preparation of a medicine for treating secondary lymphedema. According to the application, the S100A8 / A9 dimer small-molecule inhibitor Paquinimod is used for treating mice with lymphedema, and a result shows that the Paquinimod can be used for remarkably inhibiting secretion of inflammatory factors of the model mice, effectively relieving the edema condition and inhibiting activation of an S100A8 / A9-TLR4-CCL2 signal channel. Therefore, the inhibitor Paquinimod of the S100A8 / A9-TLR4 signal channel is applied to preparation of the medicine for treating the secondary lymphedema (SL), a new thought and a new method are developed for treatment of the SL, and the problem that the SL lacks an effective treatment means is effectively solved.

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product FDP antibody and application thereof. According to the present invention, the single B cell antibody preparation technology and the flow cytometry sorting method are firstly applied to the blood coagulation in vitro diagnosis fibrinolysis system detection antibody development, and the mammalian cell expression system is adopted to successfully express and obtain the three FDP monoclonal antibody strains (the numbers are FDP-1, FDP-2 and FDP-3) with the biological activity; on an ELISA (enzyme-linked immuno sorbent assay) platform, the three FDP recombinant rabbit monoclonal antibodies have specific reaction with primary fibrinolytic substances (X and Y) and secondary fibrinolytic substances (DD); on an immunoturbidimetric platform, the FDP-1 has specific reaction with the primary fibrinolytic substance and the secondary fibrinolytic substance, and the FDP-2 only has specific reaction with the primary fibrinolytic substance on the immunoturbidimetric platform. The three FDP antibodies provided by the invention can make up the vacancy of domestic FDP antibodies on the market, ensure the joint monitoring suitability of D-dimer and FDP, and realize the detection integrity of fibrinolytic system.

The present invention relates to antibody conjugates which are particularly suitable for targeting CEA-expressing cells, in particular tumor cells. An antibody conjugate according to the present invention has the structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing CEA; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w'is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus hemiphyllum, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine # imgabs 0 # dimer or a pyrrolo-benzodiazepine # imgabs 1 # dimer (PBD), and analogs or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The invention relates to a dimer non-fullerene acceptor molecule based on a pyrone-ring lock structure, preparation of the dimer non-fullerene acceptor molecule and application of the dimer non-fullerene acceptor molecule as an acceptor photovoltaic material, and belongs to the technical field of organic solar cell materials. An A-D-A '-D-A type dimer non-fullerene acceptor molecule is designed and synthesized based on a pyrone structure, A is an electron withdrawing unit, D is an electron donating unit, and A' is an electron withdrawing unit based on the pyrone structure. The dimer molecule has a structural general formula I shown in the specification. Wherein EG is selected from conjugated groups with electron withdrawing capability, Ar is selected from conjugated groups with electron donating capability, and X is selected from hydrogen atoms or halogen. The dimer acceptor molecule shows a small dihedral angle, which is beneficial to accumulation between molecules, so that the material has high carrier mobility. The dimer acceptor molecule with the pyrone structure shows obviously improved stability under illumination and attack of a nucleophilic reagent, and the organic solar cell device shows good photoelectric conversion efficiency.